Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis : The 2022 Update
Copyright © 2022 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease..
In the last few decades, there has been a progressive increase in the prevalence of allergic rhinitis (AR) in China, where it now affects approximately 250 million people. AR prevention and treatment include allergen avoidance, pharmacotherapy, allergen immunotherapy (AIT), and patient education, among which AIT is the only curative intervention. AIT targets the disease etiology and may potentially modify the immune system as well as induce allergen-specific immune tolerance in patients with AR. In 2017, a team of experts from the Chinese Society of Allergy (CSA) and the Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G) produced the first English version of Chinese AIT guidelines for AR. Since then, there has been considerable progress in basic research of and clinical practice for AIT, especially regarding the role of follicular regulatory T (TFR) cells in the pathogenesis of AR and the use of allergen-specific immunoglobulin E (sIgE) in nasal secretions for the diagnosis of AR. Additionally, potential biomarkers, including TFR cells, sIgG4, and sIgE, have been used to monitor the incidence and progression of AR. Moreover, there has been a novel understanding of AIT during the coronavirus disease 2019 pandemic. Hence, there was an urgent need to update the AIT guideline for AR by a team of experts from CSA and C2AR2G. This document aims to serve as professional reference material on AIT for AR treatment in China, thus improving the development of AIT across the world.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Allergy, asthma & immunology research - 14(2022), 6 vom: 25. Nov., Seite 604-652 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Chengshuo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergen immunotherapy |
|---|
| Anmerkungen: |
Date Revised 17.12.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4168/aair.2022.14.6.604 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349394458 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349394458 | ||
| 003 | DE-627 | ||
| 005 | 20231226042523.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4168/aair.2022.14.6.604 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349394458 | ||
| 035 | |a (NLM)36426395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Chengshuo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis |b The 2022 Update |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease. | ||
| 520 | |a In the last few decades, there has been a progressive increase in the prevalence of allergic rhinitis (AR) in China, where it now affects approximately 250 million people. AR prevention and treatment include allergen avoidance, pharmacotherapy, allergen immunotherapy (AIT), and patient education, among which AIT is the only curative intervention. AIT targets the disease etiology and may potentially modify the immune system as well as induce allergen-specific immune tolerance in patients with AR. In 2017, a team of experts from the Chinese Society of Allergy (CSA) and the Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G) produced the first English version of Chinese AIT guidelines for AR. Since then, there has been considerable progress in basic research of and clinical practice for AIT, especially regarding the role of follicular regulatory T (TFR) cells in the pathogenesis of AR and the use of allergen-specific immunoglobulin E (sIgE) in nasal secretions for the diagnosis of AR. Additionally, potential biomarkers, including TFR cells, sIgG4, and sIgE, have been used to monitor the incidence and progression of AR. Moreover, there has been a novel understanding of AIT during the coronavirus disease 2019 pandemic. Hence, there was an urgent need to update the AIT guideline for AR by a team of experts from CSA and C2AR2G. This document aims to serve as professional reference material on AIT for AR treatment in China, thus improving the development of AIT across the world | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allergen immunotherapy | |
| 650 | 4 | |a China | |
| 650 | 4 | |a allergic rhinitis | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a house dust mites | |
| 650 | 4 | |a immunoglobulin E | |
| 650 | 4 | |a rush immunotherapy | |
| 650 | 4 | |a subcutaneous immunotherapy | |
| 700 | 1 | |a Bao, Yixiao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yin Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Chuangli |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, He |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Huabin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Changshan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Hongfei |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Nong, Guangmin |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Qianhui |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Xiumin |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yi-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Xi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yuxin |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Suping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongtian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiangdong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xueyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhenlin |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Qingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Zhimin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qintai |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Hongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a You, Yiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Hongmeng |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Huanping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Gehua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhi, Yuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Weikang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xinhua |e verfasserin |4 aut | |
| 700 | 1 | |a Chai, Ruonan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Dehua |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zizhen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yanran |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Yuemei |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Yifan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianxing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Xian, Mo |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Luo |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese Society of Allergy (CSA) and Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergy, asthma & immunology research |d 2009 |g 14(2022), 6 vom: 25. Nov., Seite 604-652 |w (DE-627)NLM195747658 |x 2092-7355 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:6 |g day:25 |g month:11 |g pages:604-652 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4168/aair.2022.14.6.604 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 6 |b 25 |c 11 |h 604-652 | ||